Nykredit A S Invests $4.87 Million in Kenvue Inc. $KVUE

Nykredit A S bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 254,719 shares of the company’s stock, valued at approximately $4,868,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Elyxium Wealth LLC purchased a new stake in Kenvue during the 4th quarter worth about $26,000. Johnson Financial Group Inc. purchased a new stake in Kenvue in the second quarter valued at approximately $26,000. MV Capital Management Inc. purchased a new stake in shares of Kenvue during the 4th quarter valued at $28,000. CoreCap Advisors LLC increased its stake in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 591 shares during the last quarter. Finally, Reflection Asset Management acquired a new stake in Kenvue during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.2%

KVUE stock opened at $18.70 on Monday. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $20.69. The company has a market capitalization of $35.92 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 1.67 and a beta of 0.46. The firm’s 50-day moving average is $19.19 and its two-hundred day moving average is $18.26. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.29 earnings per share. On average, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were paid a dividend of $0.21 per share. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a yield of 4.5%. The ex-dividend date of this dividend was Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is currently 96.55%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. UBS Group lowered their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Barclays lifted their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Finally, Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, Kenvue currently has an average rating of “Hold” and an average target price of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.